DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dogwood Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.21−0.01 (-0.82%)
Close on Oct 19, 2026
- Market cap
- $41.30M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.55 (−78.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $41.30M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.60
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$36.04M
- EPS, diluted
- -$7.13
- Book value per share
- $2.00
- Diluted shares
- 34M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$38.76M
Net income
-$36.04M
EPS, diluted
–
Reported periodTrailing twelve months